Oxford BioMedica and FFB continue Stargardt disease agreement
This article was originally published in Scrip
Executive Summary
The Foundation Fighting Blindness (FFB) has continued its collaborative agreement with Oxford BioMedica, announcing a $250,000 investment in the company's novel gene therapy for Stargardt disease, StarGen.